Nippon India Pharma Fund - Growth has delivered CAGR and average rolling returns as follows :
1 Year | 3 Year | 5 Year | 9 Year | |
CAGR(%) | 58.49 | 19.68 | 23.1 | 13.46 |
Average Rolling Returns(%) | 18.50 | 17.53 | 15.92 | 18.60 |
The Current NAV of Nippon India Pharma Fund - Growth is ₹418.11.
You should look for a fund with better more consistent performance track record. Funds returns are more likely to be different than its benchmark S&P BSE Health Care - TRI returns, as Funds portfolio is significantly different.
Nippon India Pharma Fund - Growth fund’s expense ratio is 1.83%
The process for redemption is
The AUM of Nippon India Pharma Fund - Growth is currently ₹7,125 Crores.
The Top three stocks are Sun Pharma Inds., Lupin and Cipla and account for 30% of its portfolio. Top 5 and 10 stocks of fund account for 40% and 60% of fund’s portfolio respectively.
Top three sectors of Nippon India Pharma Fund - Growth fund are Healthcare, Miscellaneous and Others accounting for 100% of the total portfolio.
Funds Portfolio Quality is Very Good. It has a large proportion of Green Stocks.Since this is a Equity - Sectoral Fund - Pharma & Health Care it is comparatively safer to invest in this fund. However, since it has not consistently outperformed its benchmark index on an average 3-year rolling returns basis it is not the most suitable fund for SIP.
The category of Nippon India Pharma Fund - Growth Fund is Equity - Sectoral Fund - Pharma & Health Care.
Sailesh Raj Bhan manages the Nippon India Pharma Fund - Growth Fund.
Nippon India Pharma Fund - Growth current PE ratio is 51.54 and PB ratio is 7.75
The asset allocation of Nippon India Pharma Fund - Growth is Stocks : 97.15%, Debt : 1.44% and Gold : 1.41%
The minimum SIP amount for Nippon India Pharma Fund - Growth is ₹100.00 and minimum lumpsum is ₹5000.00
The exit load for Nippon India Pharma Fund - Growth is 1% on or before 1 months, Nil after 1 months